Glucagon like peptide 1 receptor agonists: therapy for diabetes management

Authors

  • Natalia Andrea Rojas Hospital Pablo Tobón Uribe
  • Elkyn Johan Granados Vega Hospital Pablo Tobón Uribe

DOI:

https://doi.org/10.21615/cesmedicina.32.1.3

Abstract

Introduction: Glucagon-like peptide 1 agonists inhibit glucose-dependent glucagon secretion, decrease gastric emptying and appetite through neural mechanisms, contribute to glucose regulation and show reduction in glycated hemoglobin A.

Methods: A bibliographic search was made on Medline® about pharmacology of the agonist glucagon-like peptide-1 receptor , Liraglutide, Lixisenatide, Albiglutide, Exenatide, Exenatide with long-acting release.

Results: The GLP1 receptor agonist are agents involved with glycemic balance, weight loss induction and are associated with lower risk of hypoglycemia. They have shown efficacy in the treatment of hypoglycemia in patients with type-2 diabetes.

Conclusions: GLP1 receptor agonist are part of the therapies for diabetes that have shown benefits in metabolic control, effectiveness in weight reduction and changes in glycated hemoglobin. More studies are needed to evaluate its long-term safety.

Downloads

Download data is not yet available.

Author Biographies

Natalia Andrea Rojas, Hospital Pablo Tobón Uribe

Química Farmacéutica

Magister en Epidemiología

Elkyn Johan Granados Vega, Hospital Pablo Tobón Uribe

Hospital Pablo Tobón Uribe

Magister en Epidemiología

Published

2017-11-21

How to Cite

Rojas, N. A., & Granados Vega, E. J. (2017). Glucagon like peptide 1 receptor agonists: therapy for diabetes management. CES Medicina, 32(1), 23–30. https://doi.org/10.21615/cesmedicina.32.1.3

Issue

Section

Revisión de tema
Article metrics
Abstract views
Galley vies
PDF Views
HTML views
Other views